Navigation Links
Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
Date:2/12/2013

alysts at 9:00 a.m. ET today. On the call, Michael Davin and Timothy Baker, the Company's Executive Vice President and Chief Financial Officer, will discuss Cynosure's financial results and provide a business overview. Those who wish to listen to the conference call webcast should visit the "Investor Relations" section of the Company's website at www.cynosure.com. The live call can also be accessed by dialing (877) 709-8155 or (201) 689-8881. If you are unable to listen to the live call, the webcast will be archived on the Company's website.

About CynosureCynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, remove multi-colored tattoos, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite and treat onychomycosis. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.

Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about future growth and commercialization or potential market acceptance of PicoSure, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Liti
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cynosure Receives FDA Clearance for At-Home Device for the Treatment of Wrinkles
2. Cynosure Announces Upcoming Conference Presentations
3. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
4. Cynosure, Inc. Prices Public Offering of Class A Common Stock
5. Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
6. Cynosure to Host Fourth-Quarter 2012 Financial Results Conference Call on February 12
7. Cynosure to Participate in Leerink Swann Global Healthcare Conference 2013
8. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
10. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
11. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014   Memorial Hermann Health System and ... announced a new partnership to provide a new level of ... centers in the greater Houston area. ... the exclusive provider of professional breast radiology services for five ... City, The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... Aug. 21, 2014 Nektar Therapeutics (NASDAQ: ... today announced positive results from its Phase 3 ... extended half-life recombinant factor VIII (rFVIII) treatment for ... which met its primary endpoint in reducing annualized ... to the on-demand arm. Top-line results ...
(Date:8/21/2014)... , Aug. 21, 2014 The spinal column ... the human body. Signals carried to and from the brain ... skills and nervous system. Injury or ailment here can be ... with a loss of control over their body. Though back ... a person,s life, there are more options available to make ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... CHAPEL HILL, N.C., Sept. 24 As the bio-pharmaceutical ... area of Oncology are tailoring their market education strategies ... their therapeutic area. Leading organizations have found that a ... product launch as KOLs, physicians, and payers in the ...
... WASHINGTON, Sept. 24 OrbusNeich today announced at the ... of patient enrollment in the randomized clinical trial of ... 183 patients included at sites in Asia, Australia, Europe ... this study represents a significant milestone as we look ...
Cached Medicine Technology:Effectively Educating the Marketplace to Support a Successful New Oncology Product Launch 2Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent 2Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent 3
(Date:8/22/2014)... autoimmune disease that affects 1 to 2 percent ... with pain, disability and joint disfigurements, but also ... and marital functioning. While many pharmacological advances help ... common. In addition, some patients avoid newer medications ... Because of this, there is interest in psychosocial ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... Dr. Sen and Dr. Samantha Pearson to help people ... and avoid corrective vision surgery by instead improving their ... prompting an investigative review. , “There’s a reason ... dollars in revenue each year—it’s because people just assume ...
(Date:8/22/2014)... 2014 Testosterone treatment lawsuits ( ... courts on behalf of men who allegedly suffered ... prescription low testosterone therapies, Bernstein Liebhard LLP reports. ... filed against Pfizer Inc. on July 31st by ... issues due to his use of Depo-Testosterone. (Case ...
(Date:8/22/2014)... 22, 2014 Mueller Sports Medicine is ... an exciting new product that provides non-drug instant relief ... active while you heal. The package includes 7 days ... new technology – it is not kinesiology tape. It’s ... PFTape™ System for Plantar Fasciitis is a breakthrough ...
(Date:8/22/2014)... 22, 2014 The improved access to ... in the developing world, has led to the decline ... of deaths due to AIDS globally. However, despite the ... of new patients becoming affected by the virus is ... undertaken by all related organisations and stakeholders, by 2015, ...
Breaking Medicine News(10 mins):Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3
... stop trial-and-error warfarin dosing , FRIDAY, Sept. 7 (HealthDay ... anti-clotting drug warfarin should make it easier to prescribe ... , Up to this point, doctors have had to ... left patients at risk of hemorrhaging from low doses ...
... Ability to Improve Patient Care, LYNWOOD, Calif., ... Center have reached a tentative agreement on a ... increase their ability to,advocate for improved patient care, ... qualified and skilled staff. The agreement, which ...
... Concentra ("Concentra" or the,"Company"), a leader in on-site ... at the construction site of the former World,Trade ... workers a,convenient way to treat work related injuries. ... site treat construction,personnel, building partners, and other individuals ...
... AdvaMed General Counsel,Christopher White issued the following statement ... Patent Reform Act of 2007:, "The closely ... the significant bipartisan opposition to the patent reform,plan ... by,making patents easier to challenge and cheaper to ...
... Zimmer,Holdings, Inc. (NYSE: ZMH ; SWX: ZMH), ... (TSX-Venture: OSH), a leader in computer,navigation for orthopaedic ... Acquisition Co., has mailed today its offer and,circular ... takeover bid for all of ORTHOsoft,s outstanding common ...
... 650,000 hospital visits, U.S. study finds , FRIDAY, Sept. 7 (HealthDay ... both the little one and his or her family from getting ... U.S. children between six months and five years old got their ... visits due to flu could be prevented. , "We found that ...
Cached Medicine News:Health News:Researchers Find Better Way to Deliver Blood Thinner 2Health News:Workers Win Contract at St. Francis Medical Center 2Health News:Concentra Opens On-Site Medical Unit at World Trade Center Site 2Health News:Zimmer Holdings Offer and ORTHOsoft Directors' Circular Mailed to Shareholders 2Health News:Zimmer Holdings Offer and ORTHOsoft Directors' Circular Mailed to Shareholders 3Health News:Zimmer Holdings Offer and ORTHOsoft Directors' Circular Mailed to Shareholders 4Health News:Child's Flu Shot Helps Whole Family 2
Transcranial Doppler dedicated to intensive care unit and operating theatre....
The Spencer Technologies PMD 100 (TCD 100M) is the worlds first stand-alone digital transcranial doppler system....
Flagship Transcranial Doppler system with multiple channel options, multi-depth options....
The portable, cost-effective system designed for fast studies and bedside reporting. The size, features and cost make this a perfect unit for a new practice, or as a second or third unit for larger h...
Medicine Products: